1.) Jody Harris is standing for election integrity! Read her lawsuit against the Crawford County Election Commission here: https://reopenarkansas.org/2022/06/14/jody-harris-lawsuit/
2.) Stacy Washington will be speaking at the Faulkner County Republican Women’s 6th Annual Flag Day dinner. On June 23rd @ 6:00 pm. If you would like tickets or more information please contact me 5015813560 or email rbmakeadifference@gmail.com
3.) FDA Sued Over Hiding Records From Moderna COVID-19 Vaccine Approval
Defending the Republic, a Texas-based non-profit filed a Freedom of Information Act lawsuit against the Food and Drug Administration for refusing to turn over records related to the approval of Moderna’s COVID-19 vaccines.
The group filed a Freedom of Information Act (FOIA) request seeking the production of records relating to the Food and Drug Administration’s (FDA) internal review process of Moderna’s COVID-19 vaccine marketed as “Spikevax.” Given that the forces impacting the FDA’s decision to authorize the vaccine could have influenced Americans’ decision on whether or not to get vaccinated against COVID-19, Defending the Republic requested expedited processing of relevant records.
“Please provide all data and information submitted by Moderna relating to the FDA review and approval of Spikevax. This includes, but is not limited to, all safety and effectiveness data and information; all data and information in the biological product file; and all ingredients,” outlined the initial FOIA request.
On February 9th, less than a week after the initial FOIA was filed, the FDA refused the request for expedited processing, prompting Defending the Republic to appeal the decision.
“The FDA declined the appeal, leaving Defending the Republic with no choice but to file this action seeking a court order requiring the FDA produce the requested records on an expedited schedule— just as those who obtained a court order for the expedited production of records relating to the FDA approved Pfizer-BioNTech vaccine,” explains a complaint filed by Defending the Republic.
Defending the Republic was especially interested in better understanding the review process for Moderna’s COVID-19 vaccine, as data has shown its risk were not adequately explained to those receiving it and data surrounding its efficacy remains obscured. As Defending the Republic explains:
Despite the FDA’s promises, a closer inspection of the Spikevax approval reveal there may be glaring issues in the approval process. The Spikevax package insert concedes “[a]vailable data on SPIKEVAX administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.”
And while the FDA publicly pronounced that the “data demonstrated that Spikevax was 93% effective in preventing COVID-19,” the Spikevax fact sheet for recipients and caregivers provides important context omitted by the public officials: “The [Spikevax] duration of protection against COVID19 is currently unknown.
The lawsuit comes amidst several National Pulse exposés revealing how lobbyists from pharmaceutical companies including Moderna have entrenched themselves within Washington, D.C.
4.) Cancer Trial Using Monoclonal Antibody Finds Remission in Every Patient
A cancer trial has reportedly become the first in the world to completely remove the disease in every patient, according to a study published on June 5 in The New England Journal of Medicine.
The study, “PD-1 Blockade in Mismatch Repair—Deficient, Locally Advanced Rectal Cancer,” was conducted among 12 rectal cancer patients, all of whom had a “clinical complete response,” according to the authors, led by Dr. Andrea Cercek of the Memorial Sloan Kettering Cancer Center in New York.
Doctors have been unable to see any evidence of tumors among the patients when using magnetic resonance imaging, fludeoxyglucose F 18 injections, physical examinations, or endoscopic evaluations, according to researchers.
The patients also continued to show no signs of cancer during follow-ups ranging from six months to 25 months and haven’t had to undergo surgery or receive radiation and chemotherapy. “No adverse events of grade 3 or higher have been reported,” the study authors noted.
Specifically, the rectal cancer patients were given dostarlimab, a monoclonal antibody, every three weeks for six months. The patients had mismatch repair-deficient stage two or three rectal adenocarcinomas, a type of cancer.
Typically, such cancer patients would have needed to undergo often debilitating treatments such as chemotherapy, radiation, or surgery, and in extreme cases be fitted with colostomy bags. However, after taking dostarlimab, which is sold under the brand name Jemperli, no cases of progression or recurrence were reported in the patients who underwent the study.
Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, author of the study, told The New York Times that he believes this is the “first time this has happened in the history of cancer.”